Overview

Descartes-08 for Patients With Systemic Lupus Erythematosus

Status:
RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
Phase:
PHASE2
Details
Lead Sponsor:
Cartesian Therapeutics